Stock MarketROI
Open
BAX

BAX

Healthcare · Medical Instruments & Supplies

$20.73-0.38%
Mkt Cap: $10.71BDY: 0.96%

Performance

BAX (BAX) Stock Analysis 2026

Rule-based · Updated daily · Not financial advice

BAX (BAX) operates in the Medical Instruments & Supplies space within the Healthcare sector. With a market cap of $10.7B, it qualifies as a mid-cap company. Growth is moderate and the business remains profitable, offering a balanced risk/reward profile compared to high-multiple peers.

Bull Case1
  • Low beta of 0.64 — less volatile than the market, suitable for conservative portfolios
Bear Case3
  • Negative profit margin of -9.7% — company is currently unprofitable
  • Negative ROE of -15.0% — shareholder equity is being eroded
  • High debt-to-equity of 161.02× increases financial risk, especially with elevated interest rates

Verdict

Avoid

Significant fundamental concerns outweigh positives. High risk at current levels.

AI Insight

Powered by Claude

AI-generated analysis for informational purposes only. Not financial advice.

Related Articles

Revenue & Results

Dividends

Current DY

0.96%

5Y Avg Annual

$0.7780

Last Payment

$0.0100

Ex-Date

05/29/2026

Annual dividends paid per share

2011
2019
2026
Ex-DatePaymentAmountEst. DY
Latest05/29/2026
07/01/2026$0.01000.19%
02/27/2026
04/01/2026$0.01000.19%
11/28/2025
12/31/2025$0.01000.19%
08/29/2025
10/01/2025$0.17003.28%
05/30/2025
07/02/2025$0.17003.28%
02/28/2025
04/02/2025$0.17003.28%
11/29/2024
01/01/2025$0.17003.28%
08/30/2024
10/02/2024$0.29005.60%

Magic Number

Shares needed to self-fund your next purchase

$20.73

Price

÷

$0.0100

Last div. (quarterly)

=

2,073

shares

Own 2,073 BAX shares ($42,973.29) and each quarterly dividend pays for 1 new share — the snowball runs on its own.

Investment target

$42,973.29

New shares / year

+4 shares

If You Had Invested…

Hypothetical return based on historical prices

$

* Dividend reinvestment calculated at ex-date price. For informational purposes only.

Earnings

Next Earnings

Jul 30, 2026

44

days

EPS (TTM)

$-1.91

P/E (TTM)

Fwd P/E

10.3

Earnings History

SEC EDGAR · official filings

SEC filings

SEC Filings

Official EDGAR documents

All filings

Key Statistics

Valuation

Market Cap$10.71B
P/E Ratio
Forward P/E10.30
P/B Ratio
PEG Ratio36.68
EPS (TTM)$-1.91

Trading

Open
Day High
Day Low
52W High$31.76
52W Low$15.73
Volume
Avg Volume (3M)7,616,714
Beta0.64

Dividends

Dividend Yield0.96%
Annual Rate$0.20
Ex-Div Date2026-05-29
Payout Ratio307.69%

Profitability

Profit Margin-9.70%
Operating Margin6.03%
ROE-15.01%
ROA2.85%
Revenue Growth2.90%
Earnings Growth

Balance Sheet

Total Revenue$11.32B
Total Debt$9.69B
Debt / Equity161.02
Current Ratio1.85
Free Cash Flow$900.88M

Fair Value Estimates

Current price: $20.73

Graham Number

√(22.5 × EPS × Book Value)

N/A

Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.

Bazin Ceiling Price

Avg. Annual DPS (5Y) ÷ 6%

$16.52

-20.3% downside

Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.

These are simplified estimates. Not financial advice.

Buy & Hold Checklist

Quality criteria for long-term holding

6/10

67% score

Pays dividends

15Y hist.

15+ years of dividend history

Dividend consistency (5Y+)

15 yrs

Uninterrupted dividend payments for at least 5 years

ROE above 10%

-15.0%

Return on equity — measures how efficiently capital is used

Positive profit margin

-9.7%

Net profit margin must be positive — company earns more than it spends

Revenue growth (annual)

+2.9%

Annual revenue must be growing compared to the prior year

Earnings growth (annual)

Annual earnings must be growing compared to the prior year

Debt/Equity below 2×

161.02×

Low financial leverage reduces risk of distress

Current ratio above 1

1.85×

Short-term assets must cover short-term liabilities

Daily liquidity above $5M

$158M/day

High trading volume ensures easy entry and exit

Dividend yield above 0%

0.96%

Stock must distribute income to shareholders

Related Assets

Healthcare

About BAX

Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Sector

Healthcare

Industry

Medical Instruments & Supplies

Location

Deerfield, United States

Employees

37,500